Centro Hospitalar E Universitario De Coimbra E.P.E.

The Centro Hospitalar E Universitario De Coimbra E.P.E. Neurology department is conducting research aimed at preventing and treating cerebrovascular events, with a focus on acute ischemic stroke and high‑risk transient ischemic attack. A key study evaluates the safety and efficacy of milvexian to lower the risk of recurrent stroke.

• Acute Ischemic Stroke
• High‑Risk Transient Ischemic Attack
• Antithrombotic Therapy Development
• Risk Reduction Strategies

Investigators are exploring novel anticoagulant approaches to improve outcomes for patients at high risk of cardiovascular complications.

In the realm of neurodegenerative and epileptic disorders, the site is testing innovative therapies for Alzheimer's disease and primary generalized tonic‑clonic seizures. One trial measures amyloid reduction with ABBV‑916 in early Alzheimer’s, while another assesses the impact of XEN1101 on seizure frequency.

• Early Alzheimer’s Disease
• Amyloid Targeting Strategies
• Primary Generalized Tonic‑Clonic Seizures
• Seizure Frequency Reduction

The multidisciplinary team aims to bring disease‑modifying treatments to patients with cognitive decline and epilepsy.

The hospital participates in an adaptive platform trial addressing COVID‑19, evaluating therapeutic options for both moderate and severe disease. A specific protocol compares baricitinib plus standard of care against placebo in immunocompromised patients with critical illness.

• Moderate COVID‑19
• Severe/Critical COVID‑19
• Adaptive Pandemic Platform
• Immunocompromised Patient Care

These efforts contribute to global knowledge on effective interventions during the pandemic and support vulnerable patient groups.